A
Alcista
Alcista · 25%CNMD
$71.75
Precio del escenario
$46.720
-0.416 (-0.89%)Al cierre
Loading chart…
- Máximo
- 47.800
- Apertura
- 47.320
- Precio medio ponderado por volumen
- 47.01
- Volumen
- 413.97K
- Capitalización
- 2.08B
- Mínimo
- 46.500
- Importe
- 19.46M
- EV/EBITDA, TTM
- 7.83
CONMED Corporation is a medical technology company which provides devices and equipment for surgical procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product line consists of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments.
Análisis de IA of Conmed Corp (CNMD)
MantenerConmed Corp (CNMD) is currently trading at $44.42, which is significantly below the average analyst target price of $111.62. However, the stock has a low RSI of 37.506, indicating it may be oversold. The forward P/E ratio is 27.17, suggesting that the stock is relatively expensive compared to its earnings potential. The recent 5-day change is -4.10%, indicating a downward trend, while the YTD change is +9.62%, showing overall positive performance this year. The main risk is the recent downgrade by BofA to Underperform with a target of $40, which could indicate further downside potential. Overall, while there are positive catalysts such as earnings beats and revenue growth, the current technical indicators and analyst sentiment suggest holding off on buying until more favorable conditions arise.
Recomendaciones de analistas (6)
+7.02% de potencial alcista
Mantener
2 Comprar
4 Mantener
0 Vender
Actual: 46.72
Mínimo
41.00
Promedio
50.00
Máximo
55.00
JPMorgan
Neutral
$45
2026-07-30
JPMorgan
2026-07-30
Precio objetivo
$45
Neutral
Piper Sandler
Neutral
$45
2026-07-30
Piper Sandler
2026-07-30
Precio objetivo
$45
Neutral
BMO Capital
Market Perform
$36
2026-07-08
BMO Capital
2026-07-08
Precio objetivo
$36
Market Perform
BofA
Inferior al mercado
$40
2026-06-29
BofA
2026-06-29
Precio objetivo
$40
Inferior al mercado
BofA
Neutral
$40
2026-05-18
BofA
2026-05-18
Precio objetivo
$40
Neutral
Métricas de valoración
El PER previsto actual de Conmed Corp (CNMD) es 27.17, frente a su media de 5 años de 24.52.
Escenarios de precio de Alphio AI para CNMD
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con CNMD en cartera
Cronología de eventos
Noticias
4.009-16NASDAQ.COMCONMED Stock Surpasses Analyst Target Price
9.507-30seekingalphaCONMED Corporation Q2 2026 Earnings Call Highlights
9.507-30NASDAQ.COMConmed Reports Q2 Earnings Beat Expectations
5.007-22NewsfilterCONMED Expands AirSeal® Robotic Solution Indication for da Vinci Systems
8.007-13NASDAQ.COMSurge in Options Trading Volume for Tripadvisor and Liquidia
Preguntas frecuentes sobre CNMD, respondidas por Alphio AI
CONMED Corporation is a medical technology company which provides devices and equipment for surgical procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product line consists of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).
Conmed Corp (CNMD) is currently trading at $44.42, which is significantly below the average analyst target price of $111.62. However, the stock has a low RSI of 37.506, indicating it may be oversold. The forward P/E ratio is 27.17, suggesting that the stock is relatively expensive compared to its earnings potential. The recent 5-day change is -4.10%, indicating a downward trend, while the YTD change is +9.62%, showing overall positive performance this year. The main risk is the recent downgrade by BofA to Underperform with a target of $40, which could indicate further downside potential. Overall, while there are positive catalysts such as earnings beats and revenue growth, the current technical indicators and analyst sentiment suggest holding off on buying until more favorable conditions arise.
6 analysts cover CNMD: 2 rate it Buy, 4 Hold and 0 Sell. The average price target is 50.00.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.